CO2020008308A2 - Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico - Google Patents

Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico

Info

Publication number
CO2020008308A2
CO2020008308A2 CONC2020/0008308A CO2020008308A CO2020008308A2 CO 2020008308 A2 CO2020008308 A2 CO 2020008308A2 CO 2020008308 A CO2020008308 A CO 2020008308A CO 2020008308 A2 CO2020008308 A2 CO 2020008308A2
Authority
CO
Colombia
Prior art keywords
relaxin
therapeutic use
chain peptides
lipidated
modified
Prior art date
Application number
CONC2020/0008308A
Other languages
English (en)
Spanish (es)
Inventor
Olivier Duclos
Stéphane Illiano
Sergio Mallart
Claire Minoletti-Hochepied
Elisabetta Bianchi
Raffaele Ingenito
Paola Magotti
Alessia Santoprete
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO2020008308A2 publication Critical patent/CO2020008308A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/64Relaxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2221Relaxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2020/0008308A 2018-01-31 2020-07-06 Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico CO2020008308A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31
PCT/EP2019/052298 WO2019149782A1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use

Publications (1)

Publication Number Publication Date
CO2020008308A2 true CO2020008308A2 (es) 2020-10-30

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0008308A CO2020008308A2 (es) 2018-01-31 2020-07-06 Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico

Country Status (29)

Country Link
US (3) US10961295B2 (https=)
EP (1) EP3746467B1 (https=)
JP (1) JP7295871B2 (https=)
KR (1) KR102755938B1 (https=)
CN (1) CN111770934B (https=)
AR (1) AR114325A1 (https=)
AU (1) AU2019214358B2 (https=)
BR (1) BR112020014834A2 (https=)
CA (1) CA3089657A1 (https=)
CO (1) CO2020008308A2 (https=)
DK (1) DK3746467T3 (https=)
ES (1) ES3058633T3 (https=)
FI (1) FI3746467T3 (https=)
HR (1) HRP20260016T1 (https=)
IL (2) IL316406A (https=)
LT (1) LT3746467T (https=)
MA (1) MA52994A (https=)
MX (1) MX2020008096A (https=)
MY (1) MY199821A (https=)
NZ (1) NZ766762A (https=)
PH (1) PH12020551118A1 (https=)
PL (1) PL3746467T3 (https=)
PT (1) PT3746467T (https=)
RS (1) RS67606B1 (https=)
SG (1) SG11202006903WA (https=)
SI (1) SI3746467T1 (https=)
TW (1) TWI763972B (https=)
UY (1) UY38069A (https=)
WO (1) WO2019149782A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
MA52994A (fr) 2018-01-31 2021-05-05 Sanofi Sa Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
US20240400638A1 (en) * 2021-08-23 2024-12-05 Guido MAGNI Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
KR20260035823A (ko) 2023-05-18 2026-03-13 테크토닉 오퍼레이팅 컴퍼니 인코포레이티드 렐락신-2 융합 단백질 유사체 및 이를 사용하는 방법
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0923283A2 (pt) * 2008-12-05 2017-06-06 Angiochem Inc conjugados terapêuticos de peptídeo e usos dos mesmos
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素(relaxin)融合多肽類及其用途
EP2726502A1 (en) * 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
JP6276690B2 (ja) * 2011-08-04 2018-02-07 ファリス バイオテック ゲーエムベーハー ヒトリラキシン−2を調製する方法
US20160152679A1 (en) 2012-05-24 2016-06-02 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
CN105792851B (zh) * 2013-09-13 2023-10-10 斯克利普斯研究所 修饰的治疗剂及其组合物
CA2945838C (en) * 2014-04-17 2022-08-16 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
EP3838285A1 (en) * 2014-04-22 2021-06-23 TXP Pharma GmbH Peptide analogues with branched amino acid probe(s)
CN110637027B (zh) * 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
MA52994A (fr) 2018-01-31 2021-05-05 Sanofi Sa Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique
TW201934572A (zh) * 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素b鏈胜肽及其治療用途
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
US20240400638A1 (en) * 2021-08-23 2024-12-05 Guido MAGNI Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Also Published As

Publication number Publication date
IL276170B1 (en) 2024-11-01
WO2019149782A1 (en) 2019-08-08
KR102755938B1 (ko) 2025-01-20
UY38069A (es) 2019-08-30
IL316406A (en) 2024-12-01
JP7295871B2 (ja) 2023-06-21
ES3058633T3 (en) 2026-03-12
BR112020014834A2 (pt) 2020-12-08
US20190233494A1 (en) 2019-08-01
CN111770934B (zh) 2024-10-18
TW201940505A (zh) 2019-10-16
KR20200116085A (ko) 2020-10-08
US10961295B2 (en) 2021-03-30
IL276170B2 (en) 2025-03-01
TWI763972B (zh) 2022-05-11
DK3746467T3 (da) 2026-01-12
SI3746467T1 (sl) 2026-02-27
AU2019214358B2 (en) 2023-05-25
PT3746467T (pt) 2026-01-13
RS67606B1 (sr) 2026-01-30
SG11202006903WA (en) 2020-08-28
NZ766762A (en) 2026-03-27
US20210292387A1 (en) 2021-09-23
CN111770934A (zh) 2020-10-13
EP3746467A1 (en) 2020-12-09
CA3089657A1 (en) 2019-08-08
FI3746467T3 (fi) 2026-01-16
RU2020126210A (ru) 2022-02-28
LT3746467T (lt) 2026-01-26
PH12020551118A1 (en) 2021-07-05
MY199821A (en) 2023-11-23
PL3746467T3 (pl) 2026-04-13
MA52994A (fr) 2021-05-05
US20240218042A1 (en) 2024-07-04
AU2019214358A1 (en) 2020-08-20
IL276170A (en) 2020-09-30
AR114325A1 (es) 2020-08-19
US11725036B2 (en) 2023-08-15
HRP20260016T1 (hr) 2026-02-27
MX2020008096A (es) 2020-09-24
EP3746467B1 (en) 2025-10-08
JP2021512099A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
CO2020008308A2 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
ES2619322T3 (es) Agente inductor de inmunidad
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
PE20241305A1 (es) Analogos de amilina
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
PE20160244A1 (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos
BR112018003898A2 (pt) material auxiliar para aplicação no tecido de cólon
ECSP12011803A (es) Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MX2015015500A (es) Composiciones de cenicriviroc y metodos para elaborarlas y usarlas.
MX383887B (es) Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich.
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
ES3059584T3 (en) Rhodopsin gene therapy for regenerating visual function or for preventing deterioration in visual function
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
RU2014130894A (ru) Пептид, обладающий нейропротекторной и ноотропной активностью, и фармацевтическая композиция на его основе
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
ECSP19024033A (es) Composiciones de tesofensina
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.